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Abstract
Acute promyelocytic leukemia (AML M3) is a well-defined subtype
of leukemia with specific and peculiar characteristics. Immediate
identification of t(15;17) or the PML/RARA gene rearrangement is
fundamental for treatment. The objective of the present study was to
compare fluorescent in situ hybridization (FISH), reverse transcriptase-
polymerase chain reaction (RT-PCR) and karyotyping in 18 samples
(12 at diagnosis and 6 after treatment) from 13 AML M3 patients.
Bone marrow samples were submitted to karyotype G-banding, FISH
and RT-PCR. At diagnosis, cytogenetics was successful in 10 of 12
samples, 8 with t(15;17) and 2 without. FISH was positive in 11/12
cases (one had no cells for analysis) and positivity varied from 25 to
93% (mean: 56%). RT-PCR was done in 6/12 cases and all were
positive. Four of 8 patients with t(15;17) presented positive RT-PCR
as well as 2 without metaphases. The lack of RT-PCR results in the
other samples was due to poor quality RNA. When the three tests were
compared at diagnosis, karyotyping presented the translocation in
80% of the tested samples while FISH and RT-PCR showed the PML/
RARA rearrangement in 100% of them. Of 6 samples evaluated after
treatment, 3 showed a normal karyotype, 1 persistence of an abnormal
clone and 2 no metaphases. FISH was negative in 4 samples studied
and 2 had no material for analysis. RT-PCR was positive in 4 (2 of
which showed negative FISH, indicating residual disease) and nega-
tive in 2. When the three tests were compared after treatment, they
showed concordance in 2 of 6 samples or, when there were not enough
cells for all tests, concordance between karyotype and RT-PCR in one.
At remission, RT-PCR was the most sensitive test in detecting residual
disease, as expected (positive in 4/6 samples). An incidence of about
40% of 5 breaks and 60% of 3 breaks, i.e., bcr3 and bcr1/bcr2,
respectively, was observed.
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Introduction
Acute promyelocytic leukemia (AML
M3) is characterized by the t(15;17)(q22;q11-
21) translocation described by Rowley et al.
(1). This translocation reflects the molecular
rearrangement of the PML gene, located at
15q22, with the RARA gene, located at 17q21
(2), and is considered to be critical for the
pathogenesis of the disease since it blocks
differentiation during the promyelocytic stage
of myeloid maturation (3). PML has been
shown to function as a tumor suppressor and
RARA has differentiation-promoting and
growth-suppressing activities, being essen-
tial for normal hematopoiesis. Furthermore,
the expression of PML/RARA leads to dis-
ruption of PML nuclear body structures, re-
sulting in dislocation of this growth-sup-
pressor gene (4,5) and its inhibition by the
formation of heterodimers (6).
At first, anthracyclines and cytarabine
were the treatment of choice for AML, but
after the introduction of a vitamin A deriva-
tive, all-trans retinoic acid (ATRA), at the
end of the 80s (7), a great improvement in
remission rate has been observed. ATRA
induces blasts and terminal promyelocyte
differentiation followed by cell death (8).
How ATRA overcomes the dominant nega-
tive effect of PML/RARA is not understood,
but it seems that ATRA disrupts the interac-
tion of the PML/RARA protein with the
nuclear co-repressor/histone deacetylase
complex that promotes transcriptional re-
pression (6).
Treatment with ATRA alone may induce
complete, though short-lived, remission in
more than 80% of cases (9), but when com-
bined with chemotherapy it leads to signifi-
cant improvement in survival rate and low-
ers the incidence of relapse (3,10).
Immediate identification of patients that
would benefit from ATRA became of funda-
mental importance, since those that do not
present the typical translocation will not go
into remission. This identification is usually
based on cytogenetics but t(15;17) is not
detected in at least 10% of morphologic
AML M3 due mainly to technical failure of
cytogenetic analysis, to the presence of PML/
RARA fusion genes created by cryptic inser-
tion events or to the analysis of cells not
belonging to the neoplastic clone (erythro-
blasts) (3,4). Thus, alternative methods such
as fluorescent in situ hybridization (FISH) or
reverse transcriptase-polymerase chain re-
action (RT-PCR) for the detection of PML
and RARA fusion genes or transcripts per-
mit a faster identification (11).
When patients are in clinical or hemato-
logical remission, more sensitive methods
should be used for the detection of residual
disease. RT-PCR status after completion of
therapy is of prognostic significance and
emphasizes the importance of achievement
of molecular remission as a prerequisite for
long-term survival. RT-PCR allows identifi-
cation of one abnormal cell out of 104-106
(12,13).
The objective of the present study was to
evaluate and compare FISH, RT-PCR and
karyotyping for the detection of residual AML
M3 disease.
Material and Methods
Eighteen samples (12 obtained at diagno-
sis and 6 after treatment) from 13 patients
with AML M3 were studied (Table 1) from
March 1996 to May 1999. Diagnosis was
made according to FAB criteria (14) after
total blood counts, cytochemistry, immuno-
phenotyping and cytogenetics. All patients
presented typical AML M3 morphology.
A second evaluation for the detection of
residual disease by cytogenetics, FISH and
RT-PCR was done when remission was
achieved.
Patients were treated with ATRA (45 mg
sqm-1 day-1) followed by daunorubicin (DNR;
40 mg sqm-1 day-1/3 days) and cytarabine
(araC; 200 mg sqm-1 day-1/7 days) as soon as
white blood cell count exceeded 3,000/mm3,
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as suggested by Kanamaru et al. (8). After
complete remission was obtained, three
courses of consolidation chemotherapy were
applied according to the following protocol:
mitoxantrone (MIT; 7 mg sqm-1 day-1/3 days)
and araC (80 mg sqm-1 day-1/7 days); DNR
(50 mg sqm-1 day-1/3 days), araC (200 mg
sqm-1 day-1/7 days), etoposide (ETO; 100 mg
sqm-1 day-1/5 days) and 6-mercaptopurine
(6MP; 70 mg sqm-1 day-1/5 days); epirubicin
(30 mg sqm-1 day-1/days 1 and 4) and araC
(170 mg sqm-1 day-1/7 days). Maintenance
consisted of six courses applied every 6 weeks
of araC (170 mg sqm-1 day-1/5 days), DNR
(30 mg sqm-1 day-1/days 1 and 4) and 6MP
(70 mg sqm-1 day-1/7 days); araC (170 mg
sqm-1 day-1/5 days) and MIT (5 mg sqm-1
day-1/2 days); araC (170 mg sqm-1 day-1/5
days), ETO (80 mg sqm-1 day-1/5 days) and
vinblastine (6 mg sqm-1 day-1/days 1 and 8).
Case 10 received only ATRA for induction
but his consolidation and maintenance treat-
ment was similar to that for the other pa-
tients.
Five bone marrow donor samples with
normal karyotype (from normal persons,
whose karyotypes were routinely studied
before donation for transplant) served as the
control group for FISH. The Ethics Commit-
tee of the institution approved the study and
the samples were collected after obtaining
informed consent from each patient.
Table 1. Characterization of the cases studied: samples, sex, age, date of collection, results of karyotyping,
FISH and RT-PCR considering the presence or absence of PML/RARA rearrangement at diagnosis or after
therapy.
Sample Sex Age Date Cytogenetics FISH Rearrangement
1 A M 10 6/96 46,XY,t(15;17) 57% W
B 6/97 W 4% Present (3’)
C 4/99 46,XY 3% Negative
2 A M 42 5/97 46,XY 45% W
3 A M 21 5/97 46,XY,t(15;17) 70% Present (5’)
4 A M 87 7/97 W 48% Present (5’)
B 8/97 W W Present (5’)
5 A F 30 7/97 W 68% Present (3’)
6 A M 38 10/97 46,XY,t(15;17) 25% Present (5’)
B 11/97 46,XY,t(15;17) W Present (5’)
7 A F 12 7/97 46,XX,t(15;17) 57% Present (3’)
B 10/98 46,XX 7% Present (3’)
8 A F 33 9/98 46,XX,t(15;17) 75% W
9 A F 34 9/98 46,XX,t(15;17) W W
10* A M 32 10/98 46,XY 4% Negative
11 A M 26 10/98 46,XY 55% W
12 A F 56 11/98 46,XX,t(15;17) 79% Present (3’)
13 A F 48 5/99 46,XX,t(15;17) 93% W
FISH data are reported as percentage of cells with rearrangement (normal <10%). *This sample was collected
after therapy. W = without material (metaphase, cells or RNA); M = male; F = female.
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Cytogenetics
Bone marrow was submitted to two short-
term cultures with RPMI 1640 medium, 20%
fetal calf serum, L-glutamine (1%) and antibi-
otics (1%). Colcemid (50 µl) was added for 30
min followed by KCl (75 mM), at room tem-
perature, for 20 min and Carnoys fixative for
4 times. Slides were prepared and submitted to
G-banding (GTG) and 10 metaphases from
each culture were analyzed with the aid of a
computer karyotyping system (Applied Vi-
sion, Santa Clara, CA, USA). The karyotypes
were printed with a laser printer (Lexmark)
and the abnormalities described according to
ISCN nomenclature (15) (Figure 1).
Molecular cytogenetics (FISH)
Part of the material fixed in Carnoys was
used to prepare slides for FISH, which was
carried out according to the probe suppliers
instructions (PML-RARA-Oncor, Gaithers-
burg, MD, USA). The slides were analyzed
under a fluorescent microscope (Olympus
BX60, Tokyo, Japan) with DAPI, rhodami-
ne, FITC and triple bandpass filters. The best
images were captured through a CCD cam-
era coupled to the microscope and connected
to a computer equipped with karyotyping
and FISH softwares (Applied Image). Slides
showing more than 50% cells with fluores-
cent dots were selected for analysis. Two
observers analyzed all slides. At least 200
isolated cells per slide were counted. A red
dot (rhodamine) corresponded to the RARA
(17q12) gene and a green dot (fluorescein) to
PML (15q22). Thus, when one cell with two
isolated red dots and two isolated green dots
was seen, it was counted as normal, without
rearrangement. When a cell with one iso-
lated red dot, one isolated green dot and one
fused green and red signal was seen it was
considered to present rearrangement. Cases
that presented more than 10% of cells with
rearrangement were considered to be posi-
tive. As the differences between the two
observers were less then 10%, the results
were summed and averaged.
RNA extraction and RT-PCR
Total cell RNA was extracted from leu-
kocytes with guanidinium isothiocyanate and
phenol-chloroform (16). cDNA was synthe-
sized from 1 µg of total cell RNA, using the
Not I-d(T)18 primer (Pharmacia, Uppsala,
Sweden) and M-MLV reverse transcriptase
(Pharmacia), according to suppliers instruc-
tions and using suppliers buffers. First strand
cDNA was amplified using 2.5 U of Taq
polymerase (Gibco-BRL, Gaithersburg, MD,
USA), 30 pmol of each primer: M7 (sense)
5 ATGGCTTCGACGAGTTCAAG 3 and
06 (antisense) 5 GGCTTGTAGATGCGG
GGTAG 3 (16), in a Progene thermocycler,
under the following conditions: an initial
cycle consisting of 3 min at 94oC, 90 s at
58oC and 2 min at 72oC, followed by 35
cycles at 94oC for 1 min, 58oC for 1 min and
72oC for 1 min, with a final extension step of
10 min at 72oC. Amplified RT-PCR prod-
ucts were visualized on 2% agarose gel and
photographed (Figure 2).
1 2 3 4 5
6 7 8 11 12109
13 14 15 17 1816
19 20 X Y2221
Figure 1. Karyotype showing t(15;17)(q22;q11). Arrows indicate t(15;17) translocation.
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Results
Eighteen samples from 13 patients were
studied, 12 of them obtained at diagnosis
and 6 after treatment. Seven of the 13 pa-
tients (53%) were males and 6 (46%) were
females. All had typical clinical and labora-
tory aspects of AML M3 at diagnosis. Though
case 10 had been diagnosed two years before
and was in complete remission, he was in-
cluded because he had gone into remission
with ATRA. Four cases (1, 4, 6 and 7) were
reevaluated a second or third time after treat-
ment.
Table 1 shows the results of karyotyping,
FISH and RT-PCR at diagnosis and after
therapy.
Cytogenetics was successful at diagnosis
in 10 of 12 samples (83%): 8 of them pre-
sented t(15;17)(q22;q12) and 2 had a normal
karyotype. The lack of karyotyping results in
2 samples (cases 4 and 5) was due to the
absence of metaphases or insufficient mate-
rial.
Among 6 samples evaluated a second
time after treatment, two (samples B from
cases 1 and 4) did not present enough mate-
rial for cytogenetics, three (C from case 1, B
from case 7 and A from 10) presented a
normal karyotype and one (sample B from
case 6) showed persistence of the abnormal
clone.
The results of FISH are reported as per-
centage and the 12 cases studied at diagnosis
were positive except for case 9 that did not
have sufficient material for analysis. Positiv-
ity ranged from 25 to 93% (mean, 56%).
There was a decrease in the percentage of
cells with rearrangement (or, in other words,
cells that became negative, <10%) in the
samples from patients evaluated after therapy
(1, 6, 7 and 10), except for cases 4 and 6 for
whom there was no material for FISH.
The control group for FISH presented a
mean of 5.8% cells with rearrangement with
a standard deviation of 3.3466, so the limit
for the normal value was set at 9.14%, simi-
lar to the <10% value indicated by the probe
supplier.
In the molecular study, RNA samples
that presented 18S and 28S bands after elec-
trophoresis were considered satisfactory.
Cases in which RT-PCR amplification was
not possible and whose RNA electrophore-
sis showed degraded material were consid-
ered to have technical problems and to be
without RNA (Table 1).
All procedures were carried out with a
negative control for amplification (without
cDNA), a positive control for amplification
(ß-actin), negative control for rearrangement
(normal person sample) and a positive con-
trol for rearrangement (NB4 cell lineage).
At first we tried amplification with the
same primers as Castaigne et al. (17) without
success. Then, some changes were intro-
duced and checked with the NB4 cell lin-
eage.
Using the M7-01 (M7: 5 ATg gCT TCg
ACg AgT TCA Ag 3 and 01: 5 CCA AgC
TTC TTg CAg CCC TCA CgA 3) primers
and having NB4 as template it was possible
to amplify a fragment with less than 250 bp,
which corresponded to the 230-bp fragment
found by Castaigne et al. (17). Then, by
semi-nested RT-PCR using as template the
product of the former RT-PCR and as prim-
ers the M7-06 combination (M7: 5 ATg
1 2 3 4
Figure 2. Agarose 2% gel elec-
trophoresis of RT-PCR prod-
ucts. Lane 1, 250-bp amplifica-
tion fragment using primers
M7-01; lane 2, 50-bp marker;
lanes 3 and 4, amplification
fragments using M7-06 prim-
ers being in lane 3, 350-bp
fragment and in lane 4, the 150
bp corresponding to PML gene
breakpoints bcr1/bcr3 and
bcr1/bcr2, respectively.
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gCT TCg ACg AgT TCA Ag 3 and 06: 5
ggC TTg TAg ATg Cgg ggT Ag 3), a prod-
uct of approximately 150 bp was obtained.
Using the M7-06 pair of primers we ampli-
fied fragments of 150 bp in some of our
samples and of 350 bp in others, depending
on the breakpoint of the PML gene, i.e.,
bcr1/bcr2 or bcr3, respectively (Figure 3,
Table 1).
Four of 8 patients with t(15;17) in the
karyotype also presented the molecular re-
arrangement by RT-PCR. But the lack of
results in 6 other samples was due to poor
quality RNA. Two patients with a normal
karyotype also presented poor quality RNA
and two cases that did not show karyotyping
results (cases 4 and 5) presented positive
RT-PCR.
Among the cases reevaluated after
therapy, in the second analysis (1 year after
diagnosis) case 1 presented the molecular
rearrangement by RT-PCR, though karyo-
type and FISH were negative and RNA was
of poor quality at diagnosis. At the third
evaluation (3 years after diagnosis) RT-PCR
was negative. Case 4, who had gone into
early remission, presented persistence of posi-
tive RT-PCR one month after diagnosis. Case
6 was not considered to be in remission after
one month of treatment (bone marrow with
3.4% of blasts and 16% of promyelocytes).
His karyotype showed the presence of trans-
location as well as positive RT-PCR. Case 7,
at the second evaluation was in maintenance
chemotherapy, had normal karyotype and
FISH but positive RT-PCR. Case 10 was
included because he was an AML M3 pa-
tient who went into remission with ATRA,
received the same protocol for consolidation
and maintenance and showed negative RT-
PCR as well as FISH and karyotype after
therapy.
In 6 of 18 samples it was not possible to
repeat the RT-PCR due to insufficient mate-
rial.
Discussion
AML M3 is characterized by bleeding
and used to be considered a poor prognosis
leukemia, since most patients died due to
disseminated intravascular coagulation and
fibrinolysis. However, patients who over-
came these initial problems and achieved
remission with anthracyclines and cytara-
bine had a better survival. A drastic change
in therapy occurred with the introduction of
ATRA in 1986 (7,18) .
Identification of t(15;17) or its molecular
equivalent, the rearrangement of genes PML/
RARA, continues to be the reason for cyto-
genetic, FISH and RT-PCR studies in AML
M3. Patients carrying this abnormality have
a good response to ATRA therapy, the asso-
ciated coagulopathy resolves promptly, usu-
ally within the first 48 h and remission can
be achieved in a high proportion of patients
with an increased survival rate when associ-
ated with conventional chemotherapy (19).
As expected, we observed the translocation
in 80% of the patients at diagnosis by karyo-
typing (between 70 and 95%) (19-21), but in
100% of them when the results of the three
methods were summed. Although RT-PCR
is considered to be the most valuable, it is
helpful to use FISH and karyotyping for
diagnosis, as demonstrated in the present
study and by others (or even different meth-
ods like PML immunofluorescence with spe-
cific antibodies) (4,5,21).
In the absence of the usual cytogenetic
translocation, though with typical morphol-
ogy, two events may occur: normal karyo-
type or other abnormalities, named variants,
such as t(5;17)(q32;q11), t(11;17)(q23;q11)
Figure 3. Schematic diagram of
the localization of the primers in
the PML/RARA cDNA fusion
(10).
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or t(11;17)(q13;q11), involving genes NPM/
RARA, PLZF/RARA or NuMA/RARA, re-
spectively. We did not observe variant trans-
locations (22,23) in the present study.
Some investigators considered that there
was geographical variability, with some ar-
eas presenting  a higher incidence of translo-
cations than others, but this difference was
considered to be due to technical problems
since the percentage of positive cells de-
tected by the direct method is lower than that
detected in 24-48-h cultures (24). We found
two cases with normal karyotypes (2 and 11)
by performing 24-h cultures. This proves
that cytogenetics alone is no longer consid-
ered the optimal method. Despite these limi-
tations, conventional cytogenetics should
continue to be used since complex transloca-
tions involving more than two chromosomes
or other abnormalities in addition to the
(15;17) translocation are detected only by
this method.
When there is no abnormality in the karyo-
type the molecular rearrangement may be
detected by FISH or RT-PCR and the clini-
cal course will be equal to that of patients
with the classical translocation. Two cases
with normal karyotypes presented positive
FISH in the present series.
The standardization of the PML/RARA
rearrangement by FISH and RT-PCR was
required for fast identification at diagnosis
as well as a better evaluation of minimal
residual disease or even its quantification by
FISH.
Despite the main concern about obtain-
ing enough material for all the tests we in-
tended to perform (morphology, cytochem-
istry, immunophenotyping, cytogenetics,
FISH and RT-PCR), in some cases there was
insufficient material, so that not all tests
could be performed. Whenever possible col-
lection was repeated but even then some-
times the procedure was not successful due
to technical problems or early coagulation,
which is not rare in AML M3. We had some
difficulties in obtaining material from some
patients in remission or others still receiving
chemotherapy due to marrow hypoplasia sec-
ondary to drugs (cases 1, 4 and 6 at the time
of collection of the second sample).
At diagnosis, FISH was more sensitive
than cytogenetics in detecting rearrange-
ments, and besides confirming the abnor-
mality in 7 cases with the translocation (cases
1, 3, 6, 7, 8, 12 and 13), it was positive in the
cases with normal karyotypes (cases 2 and
11) and in those that did not show meta-
phases (4 and 5). Furthermore, FISH is a fast
method providing results usually within 2
days after collection.
Comparing cytogenetics to RT-PCR at
diagnosis and when we had satisfactory RNA,
there was a good correlation between the
two methods (cases 3, 6, 7 and 12). In two
cases that did not have mitoses (cases 4 and
5) RT-PCR as well as FISH were positive.
At remission, comparison of the three
methods showed that RT-PCR, as expected,
was the most sensitive in detecting residual
disease. An interesting observation was the
presence of persistent positive RT-PCR one
year after diagnosis in two cases (cases 1 and
7) but case 1 suffered some delays in the
chemotherapy schedule due to retarded mar-
row recovering and in fact, was post-con-
solidation at the time of the second evalua-
tion.
Later, 2 or 3 years after diagnosis (cases
10 and 1, respectively), RT-PCR was nega-
tive. It seems that the time for RT-PCR to
convert to negativity is variable, with posi-
tivity continuing until about 3 months after
consolidation. It is the persistence of positiv-
ity or positivity subsequent to negativity that
represents a threat of relapse. This is why the
molecular monitoring strategies in which only
RT-PCR is determined post-consolidation
fail to predict relapse in the majority of
patients who suffer it (21).
Case 4 did not present material for karyo-
typing or FISH, but had positive RT-PCR
one month after therapy, already in complete
clinical and hematological remission, indi-
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cating the persistence of residual disease, as
expected within such a short period after
treatment.
Case 6 did not show hematological re-
mission at reevaluation after treatment and
presented persistence of  an abnormal karyo-
type and positive RT-PCR, while FISH anal-
ysis was not possible, preventing the quanti-
fication of residual cells.
Case 7 was similar to case 1, presenting
positive RT-PCR at first reevaluation, indi-
cating the presence of residual disease. In
the near future, sequential RT-PCR will show
her evolution since the patient continues to
be under treatment.
Case 10 did not have karyotyping, FISH
or RT-PCR at diagnosis and was treated for
induction with ATRA (45 mg sqm-1 day-1)
alone and then received consolidation and
maintenance  treatment as the protocol pro-
posed. At the time of collection he was 6
months out of therapy (2 years after diagno-
sis) and the three tests were negative, indi-
cating undetectable residual disease.
RT-PCR positivity after treatment may
mean amplification of one abnormal cell.
FISH may show the percentage of a greater
quantity of abnormal cells, above 10%, which
is the upper normal limit. This number does
not mean that normal subjects have rear-
rangement, but represents the cells that even-
tually have two chromosomes close to each
other, mimicking juxtaposition. Our inter-
pretation is that when the interphases were
properly swollen there was a lower number
of cells with rearrangement since the chro-
mosomes were more distant inside the
nucleus. This is why the quantification is
valid only above 10%.
Three different genomic breakpoints may
occur in the PML gene on chromosome 15q:
PML intron 3 to RARA intron 2 yielding a
PML exon 3-RARA exon 3 fusion transcript
(bcr3 or short form); PML intron 6 to RARA
intron 2 yielding a PML exon 6-RARA exon
3 fusion (bcr1 or long), and PML exon 6 to
RARA intron 2 yielding a PML partial exon
6-RARA exon 3 fusion transcript (bcr2 or
variable form) (6). We observed an inci-
dence of about 40% of 5 breaks and 60% of
3 breaks, i.e., bcr3 and bcr1/bcr2, respec-
tively, similar to other published series (21,
25). Some authors have suggested that the
presence of the 5 (bcr3) PML breakpoint is
associated with an increased risk of relapse
(12,25), while others have denied this hypo-
thesis, arguing that there are insufficient data
to justify the use of the PML breakpoint to
guide the treatment approach (21,26,27).
It was possible to standardize the two
molecular methods, FISH and RT-PCR, and
compare them. FISH was technically more
useful at diagnosis due to its rapid execution,
sensitivity and accuracy. After treatment,
RT-PCR is the method of choice.
Studies with newer technologies such as
real time PCR, which permits the quantifica-
tion of disease-related transcripts relative to
an internal control and may indicate patients
at particular risk of relapse during therapy,
are needed.
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